168 related articles for article (PubMed ID: 15618748)
1. In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole.
Emoto C; Murase S; Sawada Y; Jones BC; Iwasaki K
Drug Metab Pharmacokinet; 2003; 18(5):287-95. PubMed ID: 15618748
[TBL] [Abstract][Full Text] [Related]
2. In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations in human liver microsomes: a comparison with SKF-525A.
Emoto C; Murase S; Sawada Y; Iwasaki K
Drug Metab Pharmacokinet; 2005 Oct; 20(5):351-7. PubMed ID: 16272753
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes.
Nakajima M; Ohyama K; Nakamura S; Shimada N; Yamazaki H; Yokoi T
Drug Metab Dispos; 1999 Jul; 27(7):792-7. PubMed ID: 10383922
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions.
Katoh M; Nakajima M; Shimada N; Yamazaki H; Yokoi T
Eur J Clin Pharmacol; 2000; 55(11-12):843-52. PubMed ID: 10805063
[TBL] [Abstract][Full Text] [Related]
5. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.
Eagling VA; Tjia JF; Back DJ
Br J Clin Pharmacol; 1998 Feb; 45(2):107-14. PubMed ID: 9491822
[TBL] [Abstract][Full Text] [Related]
6. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
Wen X; Wang JS; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
[TBL] [Abstract][Full Text] [Related]
7. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes.
Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK
Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661
[TBL] [Abstract][Full Text] [Related]
8. Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes.
Cohen LH; van Leeuwen RE; van Thiel GC; van Pelt JF; Yap SH
Biopharm Drug Dispos; 2000 Dec; 21(9):353-64. PubMed ID: 11523064
[TBL] [Abstract][Full Text] [Related]
9. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.
Bourrié M; Meunier V; Berger Y; Fabre G
J Pharmacol Exp Ther; 1996 Apr; 277(1):321-32. PubMed ID: 8613937
[TBL] [Abstract][Full Text] [Related]
11. The atypical neuroleptics iloperidone and lurasidone inhibit human cytochrome P450 enzymes in vitro. Evaluation of potential metabolic interactions.
Danek PJ; Wójcikowski J; Daniel WA
Pharmacol Rep; 2020 Dec; 72(6):1685-1694. PubMed ID: 32279279
[TBL] [Abstract][Full Text] [Related]
12. A Comparison of the In Vitro Inhibitory Effects of Thelephoric Acid and SKF-525A on Human Cytochrome P450 Activity.
Song M; Do H; Kwon OK; Yang EJ; Bae JS; Jeong TC; Song KS; Lee S
Biomol Ther (Seoul); 2014 Feb; 22(2):155-60. PubMed ID: 24753822
[TBL] [Abstract][Full Text] [Related]
13. Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat.
Kobayashi K; Urashima K; Shimada N; Chiba K
Biochem Pharmacol; 2002 Mar; 63(5):889-96. PubMed ID: 11911841
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory Effects of Dimethyllirioresinol, Epimagnolin A, Eudesmin, Fargesin, and Magnolin on Cytochrome P450 Enzyme Activities in Human Liver Microsomes.
Kim JH; Kwon SS; Jeong HU; Lee HS
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28468305
[TBL] [Abstract][Full Text] [Related]
15. Isoform selective inhibition and inactivation of human cytochrome P450s by methylenedioxyphenyl compounds.
Nakajima M; Suzuki M; Yamaji R; Takashina H; Shimada N; Yamazaki H; Yokoi T
Xenobiotica; 1999 Dec; 29(12):1191-202. PubMed ID: 10647906
[TBL] [Abstract][Full Text] [Related]
16. Identification of CYP3A4 as the enzyme involved in the mono-N-dealkylation of disopyramide enantiomers in humans.
Echizen H; Tanizaki M; Tatsuno J; Chiba K; Berwick T; Tani M; Gonzalez FJ; Ishizaki T
Drug Metab Dispos; 2000 Aug; 28(8):937-44. PubMed ID: 10901704
[TBL] [Abstract][Full Text] [Related]
17. Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450-P450 and cytochrome P450-b5 interactions.
Yamazaki H; Gillam EM; Dong MS; Johnson WW; Guengerich FP; Shimada T
Arch Biochem Biophys; 1997 Jun; 342(2):329-37. PubMed ID: 9186495
[TBL] [Abstract][Full Text] [Related]
18. In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone.
Yamazaki H; Suzuki M; Tane K; Shimada N; Nakajima M; Yokoi T
Xenobiotica; 2000 Jan; 30(1):61-70. PubMed ID: 10659951
[TBL] [Abstract][Full Text] [Related]
19. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists.
Taavitsainen P; Kiukaanniemi K; Pelkonen O
Eur J Clin Pharmacol; 2000 May; 56(2):135-40. PubMed ID: 10877007
[TBL] [Abstract][Full Text] [Related]
20. The inhibitory effect of tannic acid on cytochrome P450 enzymes and NADPH-CYP reductase in rat and human liver microsomes.
Yao HT; Chang YW; Lan SJ; Yeh TK
Food Chem Toxicol; 2008 Feb; 46(2):645-53. PubMed ID: 17950511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
